Business ❯Market Analysis ❯Sales Growth ❯Forecasting
The Danish drugmaker expects U.S. Wegovy sales to recover in H2 2025 following FDA enforcement and a new CVS formulary deal, despite lowering growth forecasts due to compounding competition.